Actively Recruiting
Trigger Timing in Ovarian Stimulations
Led by Peking University Third Hospital · Updated on 2026-01-05
834
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The use of antagonist ovulation stimulation program is increasing year by year, because of its convenience, flexibility, and prevention effect of ovarian hyperstimulation syndrome. However, many researchers and clinicians believe that the clinical outcomes of antagonist regimens are worse than those of classical long-term regimens. Studies showed that the reasons for that maybe antagonist protocol results in poor effect on oocytes maturation or endometrial receptivity. At present, the trigger time of antagonist regimen is more than three follicles with diameters of ≥17 mm, which makes the duration of gonadotrophin application in antagonist regimen is shorter than that of long regimen. Whether the trigger time of antagonist regimen is too early to cause adverse effects on oocytes, embryos and eventual clinical outcomes is unknown. This study hopes to compare regular trigger timing and 1～2 days delay of trigger in ovarian stimulations by antagonist protocol，in order to study whether delay 1～2 days of trigger will get better clinical outcomes than regular trigger timing in ovarian stimulations by antagonist protocol in in vitro fertilization (IVF)/Intracytoplasmic sperm injection (ICSI). The results of this study will help infertile couples and clinicians to know and choose the optimal treatment in antagonist protocol.
CONDITIONS
Official Title
Trigger Timing in Ovarian Stimulations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 42 years old
- Antral follicle count (AFC) between 5 and 20
- Anti-mullerian hormone (AMH) level between 1.1 ng/mL and 2.5 ng/mL
- Body mass index (BMI) between 18.5 and 29 Kg/m2
- First or second assisted reproductive treatment (ART) cycle
- Regular menstrual cycles lasting between 22 and 35 days
- Presence of two ovaries
- Planned for single or double day 3 embryo transfer
- Scheduled for first IVF/ICSI cycle with fixed antagonist protocol
- Informed consent obtained
You will not qualify if you...
- Contraindications for IVF or ICSI including poorly controlled diabetes, liver disease, renal disease, significant anemia, history of blood clots or stroke, uncontrolled hypertension, symptomatic heart disease, history or suspicion of cervical, endometrial, or breast cancer, or unexplained vaginal bleeding
- Previous poor ovarian response with fewer than 4 oocytes retrieved despite high stimulation dose, or history of ovarian hyperstimulation syndrome
- Known causes of impaired implantation such as hydrosalpinx, fibroids distorting the uterine cavity, Asherman's syndrome, thrombophilia, or endometrial tuberculosis
- More than 2 previous biochemical pregnancies or spontaneous miscarriages
- More than 3 failed implantation cycles with good quality embryos
- Polycystic ovary syndrome (PCOS)
- Untreated thyroid dysfunction
- Use of exogenous estrogen, progesterone, or gonadotropins in the previous menstrual cycle
- Active female smoking
- Current pregnancy
- Previous enrollment in this trial
- Inability to understand the investigational nature of the study
- Use of donor sperm or eggs by either partner
- Use of preimplantation genetic diagnosis or screening by either partner
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Univesity Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
R
Rong Li, M.D.
CONTACT
L
Lin Zeng, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here